BamSEC and AlphaSense Join Forces
Learn More

Cara Therapeutics Inc.

NASDAQ: CARA    
Share price (12/31/24): $6.12    
Market cap (12/31/24): $28.0 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.33
from S-4 28 pages Exclusive License Agreement Re: Bcm Blg # [***]; Nih# [***] Entitled “Stat3 Inhibition to Treat Disorders Involving Mast Cell Degranulation”
12/34/56
EX-10.32
from S-4 30 pages Exclusive License Agreement Re: Bcm Blg # [***] Entitled “Chemical Probes That Competitively and Selectively Inhibit Stat3 Activation”, Developed by [***]
12/34/56
EX-10.31
from S-4 3 pages September 8, 2021 Yixin Chen, Phd Yjc999@gmail.com via E-Mail Dear Yixin, I Am Very Excited to Invite You to Join Tvardi Therapeutics, Inc. (The "Company") as We Continue to Develop Breakthrough Medicines for Cancer, Chronic Inflammation, and Fibrosis. in This Letter, I Would Like to Set Forth the Terms and Conditions of Your Employment Relationship With the Company
12/34/56
EX-10.30
from S-4 1 page Tvardi Therapeutics 2450 Holcombe Blvd, Suite X, Houston, Tx 77021 WWW.TVARDI.com
12/34/56
EX-10.29
from S-4 7 pages December 5, 2022 on Behalf of Tvardi Therapeutics, Inc. (The “Company”), I Am Pleased to Offer You Employment With the Company. the Purpose of This Letter Agreement (The “Agreement”) Is to Set Forth the Terms of Your Employment With the Company, Should You Accept Our Offer
12/34/56
EX-10.4
from 8-K 56 pages Asset Purchase Agreement by and Among Cara Therapeutics, Inc., Cara Royalty Sub, LLC and Vifor Fresenius Medical Care Renal Pharma, Ltd., Dated December 17, 2024
12/34/56
EX-10.28
from S-4 8 pages January 12, 2022 Dan Conn 205 East 69th Street, #10c New York, Ny 10021 Dear Dan: On Behalf of Tvardi Therapeutics, Inc. (The “Company”), I Am Pleased to Offer You Employment With the Company. the Purpose of This Letter Agreement (The “Agreement”) Is to Set Forth the Terms of Your Employment With the Company, Should You Accept Our Offer
12/34/56
EX-10.4
from 425 56 pages Asset Purchase Agreement by and Among Cara Therapeutics, Inc., Cara Royalty Sub, LLC and Vifor Fresenius Medical Care Renal Pharma, Ltd., Dated December 17, 2024
12/34/56
EX-10.3
from 425 4 pages Lock-Up Agreement [●], 2025
12/34/56
EX-10.27
from S-4 13 pages Imran Alibhai 4323 Cozac Lane Sugar Land, Tx 77479 Dear Imran: On Behalf of Tvardi Therapeutics, Inc. (The “Company”), I Am Pleased to Offer You Employment With the Company. the Purpose of This Letter Agreement (The “Agreement”) Is to Set Forth the Terms of Your Employment With the Company, Should You Accept Our Offer
12/34/56
EX-10.3
from 8-K 4 pages Lock-Up Agreement [●], 2025
12/34/56
EX-10.2
from 425 16 pages Support Agreement
12/34/56
EX-10.2
from 8-K 16 pages Support Agreement
12/34/56
EX-10.26
from S-4 20 pages Tvardi Therapeutics, Inc
12/34/56
EX-10.25
from S-4 10 pages Tvardi Therapeutics, Inc. Stock Option Agreement Granted Under 2018 Stock Incentive Plan
12/34/56
EX-10.1
from 8-K 11 pages Support Agreement
12/34/56
EX-10.1
from 425 11 pages Support Agreement
12/34/56
EX-10.24
from S-4 16 pages 2018 Stock Incentive Plan of Tvardi Therapeutics, Inc
12/34/56
EX-10.25
from 10-K 55 pages Purchase and Sale Agreement ​ Dated as of November 1, 2023 ​ by and Between ​ Cara Royalty Sub, LLC ​ and ​ Hcrx Investments Holdco, L.P. and Healthcare Royalty Partners IV, L.P. ​
12/34/56
EX-10.2
from 10-Q ~1 page ​ Cara Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Policy (As Amended on April 1, 2023) ​
12/34/56